Markets:

Overview

News

Currencies

International

Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

12.79 -0.19 (-1.43%)

Streaming Delayed Price Updated: 11:06 AM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 Next >

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

December 22, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

1 Small-Cap Stock to Target This Week and 2 That Underwhelm

December 17, 2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

December 09, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

December 05, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

3 Healthcare Stocks We’re Skeptical Of

December 02, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand,...

Via StockStory

Topics Stocks

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

December 02, 2025

Represents second complex respiratory therapeutic product approval in Q4 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Amneal to Participate in Upcoming Investor Conferences

December 02, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

December 01, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares? ↗

November 28, 2025

The pharmaceutical company has experienced sales growth over the past five years.

Via The Motley Fool

Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Economy

Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs ↗

November 21, 2025

One executive’s option-linked sale may look large on paper, but the broader context tells a more nuanced story.

Via The Motley Fool

Topics Regulatory Compliance

Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks

November 19, 2025

Looking back on generic pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Amneal (NASDAQ:AMRX) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Russell 2000 Stocks with Warning Signs

November 13, 2025

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...

Via StockStory

Amneal Receives U.S. FDA Approval for Iohexol Injection

November 13, 2025

First-to-market complex injectable with expected launch in Q1 2026

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

3 Stocks Under $50 We Steer Clear Of

November 11, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Via StockStory

Topics Artificial Intelligence Stocks

3 Value Stocks We Find Risky

November 09, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Why Amneal (AMRX) Stock Is Up Today

October 31, 2025

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 8.9% in the afternoon session after the company reported strong third-quarter financial results that surpassed expectations...

Via StockStory

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Q3 2025 Earnings: EPS Beats Estimates, Stock Surges on Raised Guidance ↗

October 30, 2025

Amneal Pharmaceuticals Q3 2025 earnings beat profit estimates, driving a stock surge. The company also raised its full-year guidance for EBITDA and EPS.

Via Chartmill

Topics Earnings

Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars

October 30, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.7% year on year to $784.5 million. The company’s...

Via StockStory

Amneal Reports Third Quarter 2025 Financial Results

October 30, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

October 29, 2025

Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines segment

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Amneal Earnings: What To Look For From AMRX

October 28, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Thursday before the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

October 27, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

3 Cash-Producing Stocks with Questionable Fundamentals

October 27, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

3 of Wall Street’s Favorite Stocks We Find Risky

October 14, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗

October 09, 2025

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.

Via Benzinga

Topics Government World Trade

1 Small-Cap Stock with Competitive Advantages and 2 We Turn Down

October 09, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)

October 06, 2025

From Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.